Arabic Arabic English English French French German German

Berberine is a promising therapeutic agent for myocardial ischemia/reperfusion injury.


Front Cardiovasc Med. 2021 ;8:646306. Epub 2021 May 26. PMID: 34124190

Abstract Title: 

Pre-clinical Evidence: Berberine as a Promising Cardioprotective Candidate for Myocardial Ischemia/Reperfusion Injury, a Systematic Review, and Meta-Analysis.


Myocardial ischemia/reperfusion (I/R) injury is one of the causes of most cardiomyocyte injuries and deaths. Berberine (BBR) has been suggested a potential to exert protective effects against myocardial I/R injury. This systematic review aims to determine the intrinsic mechanisms of BBR’s protective effects in myocardial I/R injury.Seven databases were searched for studies performed from inception to July 2020. Methodological quality was assessed by SYRCLE’s-RoB tool.Ten studies including a total of 270 animals were included in this study. The methodology quality scores of the included studies ranged from 5 to 7 points. The meta-analysis we conducted demonstrated that BBR significantly reduced myocardial infarct size and the incidence of ventricular arrhythmia, compared to control groups (

read more

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Berberine significantly improved the cognitive function in diabetes.

Next Post

SFD Inaugurates the Saudi Radiotherapy Center in Ar-Ramtha, Jordan

Related Posts